CN113456801A - 人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用 - Google Patents
人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用 Download PDFInfo
- Publication number
- CN113456801A CN113456801A CN202110894713.7A CN202110894713A CN113456801A CN 113456801 A CN113456801 A CN 113456801A CN 202110894713 A CN202110894713 A CN 202110894713A CN 113456801 A CN113456801 A CN 113456801A
- Authority
- CN
- China
- Prior art keywords
- preparation
- pregnancy
- chorionic gonadotropin
- human chorionic
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 102000011022 Chorionic Gonadotropin Human genes 0.000 title claims abstract description 19
- 108010062540 Chorionic Gonadotropin Proteins 0.000 title claims abstract description 19
- 229940084986 human chorionic gonadotropin Drugs 0.000 title claims abstract description 19
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 title claims description 10
- 201000004535 ovarian dysfunction Diseases 0.000 claims abstract description 6
- 229940011871 estrogen Drugs 0.000 claims description 17
- 239000000262 estrogen Substances 0.000 claims description 17
- 239000000583 progesterone congener Substances 0.000 claims description 15
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 11
- 238000009472 formulation Methods 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 claims description 9
- 230000035935 pregnancy Effects 0.000 claims description 9
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims description 6
- 229960004766 estradiol valerate Drugs 0.000 claims description 6
- 229960002985 medroxyprogesterone acetate Drugs 0.000 claims description 6
- 206010036601 premature menopause Diseases 0.000 claims description 4
- 208000017942 premature ovarian failure 1 Diseases 0.000 claims description 4
- 229960004616 medroxyprogesterone Drugs 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 7
- 230000002068 genetic effect Effects 0.000 abstract description 6
- 238000001727 in vivo Methods 0.000 abstract description 6
- 208000002193 Pain Diseases 0.000 abstract description 5
- 210000003205 muscle Anatomy 0.000 abstract description 4
- 230000007423 decrease Effects 0.000 abstract description 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 17
- 108010073521 Luteinizing Hormone Proteins 0.000 description 17
- 229940040129 luteinizing hormone Drugs 0.000 description 17
- 210000001161 mammalian embryo Anatomy 0.000 description 11
- 210000001672 ovary Anatomy 0.000 description 11
- 238000002604 ultrasonography Methods 0.000 description 7
- 229940088597 hormone Drugs 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000005906 menstruation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000004681 ovum Anatomy 0.000 description 5
- 210000002257 embryonic structure Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 210000002459 blastocyst Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000002394 ovarian follicle Anatomy 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 2
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000004858 Growth differentiation factor-9 Human genes 0.000 description 2
- 108090001086 Growth differentiation factor-9 Proteins 0.000 description 2
- 208000033830 Hot Flashes Diseases 0.000 description 2
- 206010060800 Hot flush Diseases 0.000 description 2
- 102000023108 LH Receptors Human genes 0.000 description 2
- 108010011942 LH Receptors Proteins 0.000 description 2
- 102000043136 MAP kinase family Human genes 0.000 description 2
- 108091054455 MAP kinase family Proteins 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010033122 Ovarian atrophy Diseases 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 210000001771 cumulus cell Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000011333 mature follicle stage Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100001043 ovarian atrophy Toxicity 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003765 sex chromosome Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pregnancy & Childbirth (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及制药技术领域，特别是涉及人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用。发明利用人绒毛膜促性腺激素制备的药物，通过将患者的FSH降到＜15mIU/ml，LH降到＜10mIU/ml，再一次性给患者肌肉注射HCG 10000U，可通过体内激活休眠卵泡，从而使POI患者获得带有自己遗传基因的后代，且具有经济、方便、无痛苦的优势。
Description
技术领域
本发明涉及制药技术领域，特别是涉及人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用。
背景技术
早发性卵巢功能不全(premature ovarian insufficiency，POI)是指女性在40岁之前卵巢活动衰退的临床综合征，以月经紊乱(如停经或稀发月经)伴有高促性腺激素和低雌激素为特征。POI患者的特点：卵巢卵泡耗竭缺乏生长卵泡、残留极少休眠卵泡(＜1000个)，常规促排卵药物治疗无效。POI的病因主要是性染色体及常染色体基因缺陷、自身免疫功能紊乱、感染或医源性因素等均可导致POI发生。然而，接近50％的POI病因不明确。供卵是目前最有效的治疗，但是患者无法获得带有自己遗传基因的后代。
现有一些体外激活POI患者休眠卵泡的助孕方法，如：原始卵泡体外激活(IVA)后自体移植、卵巢注射富含血小板的血浆(PRP)或干细胞、卵巢移植或线粒体替代疗法等，费用昂贵且治疗效果不确定。目前，国内外尚无体内激活休眠卵泡的研究报道。
发明内容
为了解决上述问题，本发明提供了人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用。本发明利用人绒毛膜促性腺激素制备的药物，可通过体内激活休眠卵泡，从而使POI患者获得带有自己遗传基因的后代，且具有经济、方便、无痛苦的优势。
为了实现上述目的，本发明提供如下技术方案：
本发明提供了人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用。
本发明还提供了一种早发性卵巢功能不全患者的助孕药物，所述药物包括独立包装的人绒毛膜促性腺激素。
优选的，所述药物还包括独立包装的雌激素制剂和孕激素制剂。
优选的，所述雌激素制剂包括戊酸雌二醇制剂；
所述孕激素制剂包括醋酸甲羟孕酮制剂。
优选的，所述戊酸雌二醇制剂包括补佳乐。
优选的，所述醋酸甲羟孕酮制剂包括安宫黄体酮片。
有益效果：
本发明提供了人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用。本发明利用人绒毛膜促性腺激素制备的药物，通过雌激素和/或孕激素将患者的FSH降到＜15mIU/ml，LH降到＜10mIU/ml，再一次性给患者肌肉注射HCG 10000U，可通过体内激活休眠卵泡，从而使POI患者获得带有自己遗传基因的后代，且具有经济、方便、无痛苦的优势。
附图说明
图1为实施例2中取卵后胚胎培养的阶段图，其中A为D1胚胎，B为D2胚胎，C为D3胚胎；
图2为实施例2中D5囊胚图
图3为实施例2中出生三天后的男婴图；
图4为实施例3中取卵后胚胎培养的阶段图，其中A为D1胚胎，B为D2胚胎，C为D3胚胎；
图5为实施例3中D5囊胚图；
图6为移植后28天，B超提示的宫内单活胎图。
具体实施方式
本发明提供了人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用。
本发明还提供了一种早发性卵巢功能不全患者的助孕药物，所述药物包括独立包装的人绒毛膜促性腺激素。
在本发明中，所述药物优选还包括独立包装的雌激素制剂和孕激素制剂；所述雌激素制剂优选包括戊酸雌二醇制剂；所述戊酸雌二醇制剂优选包括补佳乐；所述孕激素制剂优选包括醋酸甲羟孕酮制剂；所述醋酸甲羟孕酮制剂优选包括安宫黄体酮片。本发明对所述雌激素和孕激素的来源没有特殊要求，采用本领域技术人员所熟知的市售商品即可。
本发明利用人绒毛膜促性腺激素制备的药物，通过雌激素和孕激素将患者的FSH降到＜15mIU/ml，LH降到＜10mIU/ml，再一次性给患者肌肉注射HCG 10000U，通过注射适宜的HCG后可以增加卵泡的募集，并促进FSH诱导芳香化酶活性的提高，从而使血清中雌二醇(E2)总水平增加，进一步促进卵泡数量的募集和小卵泡的发育成熟；另外，注射适宜的HCG，可以使HCG与壁层颗粒细胞中的LH受体(LHR)结合快速诱导类表皮生长因子(EGF)表达，通过自分泌和旁分泌作用激活颗粒细胞与卵丘细胞中EGF受体(EGFR)，进而激活促进细胞增殖和分化的关键因子-丝裂原活化蛋白激酶(MAPK)，刺激颗粒细胞增殖、诱导卵丘扩张和卵母细胞成熟；同时注射适宜的HCG后可以使促黄体生成素(LH)激增，高LH增加卵源性生长因子GDF-9和骨形态发生蛋白15(BMP-15)分泌，进一步促进卵丘扩张和卵母细胞成熟；另外，激增的GDF-9还可显著增强FSH诱导的窦前卵泡体外生长，通过上述调控从而激活体内休眠卵泡(停滞于次级卵泡到成熟卵泡阶段的休眠卵泡)，进而使POI患者获得带有自己遗传基因的后代，且具有经济、方便、无痛苦的优势。
本发明优选还提供了一种早发性卵巢功能不全患者的助孕方法，包括：
通过雌激素和孕激素将患者的FSH降到＜15mIU/ml，LH降到＜10mIU/ml，再一次性给入患者人绒毛膜促性腺激素10000U。
在本发明中，所述给入的方式优选包括肌肉注射。本发明对所述注射的方式没有特殊要求，采用本领域技术人员所熟知的注射方式即可。
为了进一步说明本发明，下面结合实施例对本发明提供的人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用进行详细地描述，但不能将它们理解为对本发明保护范围的限定。
实施例1
一种早发性卵巢功能不全患者的助孕药物，所述药物由以下独立包装的制剂组成：补佳乐、安宫黄体酮片和人绒毛膜促性腺激素。
实施例2
付某，31岁，0-0-0-0，不避孕未孕1年。自23岁开始出现稀发月经，月经周期40～180天，同时伴有潮热、失眠、性交困难等症状，一直间断激素替代治疗维持正常月经。2017年4月20日外院内分泌检测：FSH 95.65mIU/ml，E212 pg/ml，LH 29.75mIU/ml。2018年3月结婚后开始备孕，每月口服芬吗通维持月经，每周或每两周B超监测卵泡，连续1年B超均提示双卵巢萎缩无卵泡。
2019年6月11日初诊。初诊当日B超：子宫大小38*42*40mm，肌层回声均匀；左卵巢12*7mm，卵巢实性，未见卵泡；右卵巢12*9mm，卵巢实性，未见卵泡。FSH 32.2mIU/ml，E250pg/ml，LH 21.91mIU/ml；AMH：＜0.01ng/ml；女方染色体核型46，XX。
治疗过程：雌激素+孕激素(每天早晚两次口服补佳乐，每次2mg+每天一次口服8mg安宫黄体酮)治疗3个月，B超监测双卵巢未发现卵泡。当患者FSH12.69mIU/ml，E297 pg/ml，LH 6.89mIU/ml时，一次性给予HCG 10000U，继续接受上述雌激素+孕激素的治疗方案，并每周一次B超监测卵泡。HCG处理后第43天，左卵巢发现1枚18.5mm的卵泡(当日激素:E2261pg/ml，FSH 4.36mIU/ml，LH 4.44mIU/ml)，立即注射曲谱瑞林0.2mg+HCG 5000U扳机，隔天取得1枚成熟卵子，培养获得1枚优胚(8CI)(图1中的C)，行冷冻保存。取卵后继续接受上述雌激素+孕激素的治疗方案，观察44天后未发现双卵巢卵泡。随后患者又注射了1次HCG10000U，但是连续观察7个月未发现卵泡。患者随后进行冻融胚胎移植助孕，并要求将胚胎解冻后继续养囊，培养2天后得到3BB囊胚1枚(图2)，移植后妊娠。2021年4月21日足月剖宫产一健康男婴(3.65kg)(出生三天后的男婴见图3)。
实施例3
卢某，31岁，1-0-0-1，不避孕未孕7年。患者7年前与现夫顺产1孩，此后未避孕一直未孕。26岁时出现月经周期提前，近2年月经周期紊乱，需要黄体酮撤退出血，1年前开始出现潮热、失眠症状，间断服用芬吗通维持月经。连续1年B超监测未见窦卵泡。2019年4月bFSH32.26mIU/ml；2019年7月bFSH 52.67mIU/ml；2020年4月FSH 64.83mIU/ml、AMH 0.01ng/ml。
2020年5月15日初诊。初诊当日B超提示双侧卵巢萎缩(Lov 12*9；Rov 12*10)，回声偏实，双卵巢无卵泡。染色体核型46，XX。FSH 36.36mIU/ml，E2105 pg/ml，LH 22.23mIU/ml。
治疗过程：雌激素+孕激素(每天早晚两次口服补佳乐，每次2mg+每天一次口服8mg安宫黄体酮)治疗3个月，B超监测双卵巢未发现卵泡。当患者FSH 13.60mIU/ml，E295 pg/ml，LH 7.33mIU/ml时，一次性给予HCG 10000U，继续接受上述雌激素+孕激素的治疗方案，并每周一次B超监测卵泡。HCG处理后第76天，左卵巢发现1枚9.5mm的卵泡(当日激素:E2107.4 pg/ml，FSH 12.98mIU/ml，LH 6.91mIU/ml)，间隔2天卵泡发育到13.5mm(当日激素:E2128.64pg/ml，FSH 9.11mIU/ml，LH 6.19mIU/ml)，间隔2天卵泡发育到15.5mm(当日激素:E2169.58 pg/ml，FSH 8.43mIU/ml，LH 5.98mIU/ml)，次日卵泡发育到17.5mm(当日激素:E2191 pg/ml，FSH 7.82mIU/ml，LH 6.27mIU/ml)，次日卵泡发育到19.0mm(当日激素:E2219pg/ml，FSH 6.32mIU/ml，LH 5.79mIU/ml)，立即注射曲谱瑞林0.2mg+HCG 5000U扳机，隔天取得1枚成熟卵子，培养获得1枚优胚(8CI)(图4中的C)，行冷冻保存。取卵后继续接受接受上述雌激素+孕激素的治疗方案，观察5个月后未发现双卵巢卵泡。患者随后进行冻融胚胎移植助孕，并要求将胚胎解冻后继续养囊，培养2天后得到3BB囊胚1枚(图5)，移植后第11天血HCG 220mIU/ml，第14天血HCG 820mIU/ml，E2437.5pg/ml，P 20.82ng/ml。移植后28天，B超提示宫内单活胎(图6)。
综上所述，本发明利用人绒毛膜促性腺激素制备的药物，可通过体内激活休眠卵泡，从而使POI患者获得带有自己遗传基因的后代，且具有经济、方便、无痛苦的优势。
虽然本发明已以较佳的实施例公开如上，但其并非用以限定本发明，任何熟悉此技术的人，在不脱离本发明的精神和范围内，都可以做各种改动和修饰，因此本发明的保护范围应该以权利要求书所界定的为准。
Claims (6)
1.人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用。
2.一种早发性卵巢功能不全患者的助孕药物，其特征在于，所述药物包括独立包装的人绒毛膜促性腺激素。
3.根据权利要求2所述的药物，其特征在于，所述药物还包括独立包装的雌激素制剂和孕激素制剂。
4.根据权利要求3所述的药物，其特征在于，所述雌激素制剂包括戊酸雌二醇制剂；
所述孕激素制剂包括醋酸甲羟孕酮制剂。
5.根据权利要求4所述的药物，其特征在于，所述戊酸雌二醇制剂包括补佳乐。
6.根据权利要求4所述的药物，其特征在于，所述醋酸甲羟孕酮制剂包括安宫黄体酮片。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110894713.7A CN113456801A (zh) | 2021-08-05 | 2021-08-05 | 人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110894713.7A CN113456801A (zh) | 2021-08-05 | 2021-08-05 | 人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113456801A true CN113456801A (zh) | 2021-10-01 |
Family
ID=77884051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110894713.7A Pending CN113456801A (zh) | 2021-08-05 | 2021-08-05 | 人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113456801A (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4291028A (en) * | 1977-12-30 | 1981-09-22 | Nichols Vorys | Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system |
| CN1346281A (zh) * | 1999-03-31 | 2002-04-24 | 赞塔里斯股份公司 | 有计划地实施受控卵巢刺激方案的方法 |
| US20180015127A1 (en) * | 2016-07-18 | 2018-01-18 | Creative Medical Technologies, Inc. | Methods for treatment of premature ovarian failure and ovarian aging using regenerative cells |
-
2021
- 2021-08-05 CN CN202110894713.7A patent/CN113456801A/zh active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4291028A (en) * | 1977-12-30 | 1981-09-22 | Nichols Vorys | Follicular phase estrogen or progestin with physiologic estrogen/progestin luteal phase replacement drug delivery system |
| CN1346281A (zh) * | 1999-03-31 | 2002-04-24 | 赞塔里斯股份公司 | 有计划地实施受控卵巢刺激方案的方法 |
| US8173592B1 (en) * | 1999-03-31 | 2012-05-08 | Zentaris Ivf Gmbh | Method for a programmed controlled ovarian stimulation protocol |
| US20180015127A1 (en) * | 2016-07-18 | 2018-01-18 | Creative Medical Technologies, Inc. | Methods for treatment of premature ovarian failure and ovarian aging using regenerative cells |
Non-Patent Citations (1)
| Title |
|---|
| 王颖等: "雌激素在不孕不育和助孕技术中的应用", 《实用妇产科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chian et al. | Pregnancies resulting from in vitro matured oocytes retrieved from patients with polycystic ovary syndrome after priming with human chorionic gonadotropin | |
| Hodgen | Surrogate embryo transfer combined with estrogen-progesterone therapy in monkeys: implantation, gestation, and delivery without ovaries | |
| Chian et al. | Natural-cycle in vitro fertilization combined with in vitro maturation of immature oocytes is a potential approach in infertility treatment | |
| US9056072B2 (en) | Hormone normalization therapy comprising administration of aromatase inhibitor, follicle stimulating hormone, luteinizing hormone, human chorionic gonadotropin, gonadotropin hormone releasing hormone and/or progesterone | |
| US5869081A (en) | Progesterone vaginal ring for treatment of infertility | |
| US6281013B1 (en) | Treatment of Infertility | |
| Mitwally et al. | Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization–embryo transfer | |
| Aaleyasin et al. | In vitro fertilization outcome following embryo transfer with or without preinstillation of human chorionic gonadotropin into the uterine cavity: a randomized controlled trial | |
| Xu et al. | Comparison of vaginal progesterone gel combined with oral dydrogesterone versus intramuscular progesterone for luteal support in hormone replacement therapy-frozen embryo transfer cycle | |
| US4725579A (en) | Method of in vitro fertilization by a unique combination of gonadotropins | |
| AU2794100A (en) | Treatment of infertility | |
| Michnova et al. | Vaginal use of micronized progesterone for luteal support. A randomized study comparing Utrogestan® and Crinone® 8%. | |
| Racca et al. | Current therapeutic options for controlled ovarian stimulation in assisted reproductive technology | |
| Xie et al. | Artificial cycle with or without a depot gonadotropin-releasing hormone agonist for frozen-thawed embryo transfer: an assessment of infertility type that is most suitable | |
| Khan et al. | Matched-samples comparison of intramuscular versus vaginal progesterone for luteal phase support after in vitro fertilization and embryo transfer | |
| Ghanem et al. | Luteal phase support in ART: an update | |
| Balmaceda et al. | Embryo implantation rates in oocyte donation: a prospective comparison of tubal versus uterine transfers | |
| Geber et al. | Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles | |
| JP2003520823A5 (zh) | ||
| CZ302835B6 (cs) | Farmaceutický prostredek | |
| CN113456801A (zh) | 人绒毛膜促性腺激素在制备早发性卵巢功能不全患者的助孕药物中的应用 | |
| JP2023527221A (ja) | 不妊症の処置における使用のためのｈｐ－ｈｍｇを含む組成物 | |
| Nyachieo et al. | Menstrual cycle synchronization, ovarian stimulation, and in vitro fertilization in olive baboons (Papio anubis): a prospective randomized study | |
| Chen et al. | The Activation of Residual Dormant Follicles by Human Chorionic Gonadotropin (HCG) in Vivo: a Novel Treatment for Premature Ovarian Insufficiency | |
| Zhang et al. | Effect of different luteal support schemes on clinical outcome in frozen‐thawed embryos transfer cycles |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211001 |